查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984154

脑造影市场：2026-2032年全球市场预测（按诊断方法、患者类型、应用和最终用户划分）

Brain Imaging Modalities Market by Modality, Patient Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑造影市场价值将达到 153.7 亿美元，到 2026 年将成长至 169 亿美元，到 2032 年将达到 310.4 亿美元，复合年增长率为 10.55%。

主要市场统计数据
基准年 2025 153.7亿美元
预计年份：2026年 169亿美元
预测年份 2032 310.4亿美元
复合年增长率 (%) 10.55%

权威概述了现代脑部影像技术，以及各种影像方式的融合如何改变临床护理和神经科学研究的进程。

脑部影像研究已发展成为一门跨学科领域，涵盖临床神经病学、外科医学、神经科学研究和生物医学工程等多个学科。设备、数据分析和示踪化学技术的进步，不仅拓展了可用的影像方式，也提高了临床医师诊断、监测和治疗神经系统疾病的准确性。因此，影像技术如今已应用于各个领域，从急性介入方案的发展到长期治疗监测，甚至包括对基本机制的阐明。

人工智慧、携带式设备、混合成像示踪剂和互通分析技术的进步如何改变临床实践、调查工作流程和诊断信心。

在技​​术创新、资料科学和不断变化的临床需求的驱动下，脑造影领域正经历着许多变革。人工智慧和先进的影像分析技术如今已能与人类解读相辅相成，显着提升了检测细微病理学变化的能力，并使得提取以往无法获得的定量生物标记成为可能。同时，高场磁振造影（HMRI）、紧凑型电脑断层扫描器）和携带式超音波设备等硬体创新，正在拓展诊断影像的施行地点，使诊断能力更贴近临床实务。

评估 2025 年关税环境将如何影响脑部影像诊断相关人员的供应可靠性、筹资策略和研究连续性。

2025年关税调整带来的政策转变对全球脑部影像硬体、耗材及配套服务的供应链产生了显着的连锁反应。对特殊零件提高进口关税，延长了大型设备和间歇性供应零件的前置作业时间，迫使製造商和医疗系统调整筹资策略。因此，采购週期延长，企业必须在资本规划中预留更大的储备金，以维持计画中的升级和安装。

透过整合模态差异、应用需求和最终用户限制的详细細項分析，指导采购、研发和临床引入策略。

基于分割的洞察揭示了在成像方式、应用和最终用户维度上，技术采纳、临床效用和研究投入分配方面的微妙模式。就影像方式而言，情况包括电脑断层扫描 (CT)、磁振造影(MRI)、光学成像、正子断层扫描 (PET)、单光子发射电脑断层扫描 (SPECT) 和超音波影像。在电脑断层扫描 (CT) 中，锥状射束CT 与传统系统的差异会影响介入和手术导航的选择。同时，磁振造影(MRI) 又细分为血管造影术、扩散影像、功能性影像和结构影像技术，以支援血管、白质、功能连接和解剖结构评估。类似地，光学影像包括功能性近红外线光谱和光学同调断层，而正子断层扫描则区分淀粉样蛋白、多巴胺和 FDG 等追踪剂。另一方面，单光子发射电脑断层扫描通常专注于多巴胺转运体成像。超音波成像技术仍分为两类：一类是用于高解析度眼科和浅层组织应用的生物显微镜，另一类是用于血流动力学监测的经颅都卜勒超音波。

区域策略分析，重点关注美洲、欧洲、中东和非洲以及亚太地区在采用率、法规、基础设施和供应链本地化方面的差异。

区域趋势正在塑造美洲、欧洲、中东和非洲（EMEA）以及亚太地区不同的技术采纳曲线、监管时间表、基础设施投资和供应链韧性。在美洲，医疗保健整合、高水准的私人投资和完善的报销机制正在推动先进影像技术的快速普及，尤其是在三级医疗中心和研究中心。同时，该地区面临着优化资本週期和强调基于价值的采购的日益增长的压力，因此更加关注那些能够展现明确成果和营运效率的解决方案。

企业策略、伙伴关係和平台方法如何整合，以加速先进脑部影像解决方案的检验和商业性部署。

脑部影像生态系统的企业发展趋势是能力融合、策略伙伴关係以及旨在弥合临床差距的定向创新。成熟的医疗设备製造商继续优先发展先进的影像处理、人工智慧成像以及将设备与全生命週期支援捆绑在一起的服务模式。同时，专业供应商和Start-Ups则专注于示踪剂开发、光学成像模组或高阶后处理分析等细分领域，以满足尚未满足的临床和研究需求，从而创造价值。

为帮助高阶主管和临床领导者增强韧性、检验创新并安全地实施诊断影像技术的进步，提供实际有效的建议。

产业领导者应采取务实、行动导向的策略，在短期业务永续营运和长期临床创新之间取得平衡。首先，应实现采购和製造合作伙伴多元化，以降低供应链中断和政策变化带来的风险，同时投资于库存视觉化工具，从而实现主动采购。其次，在选择成像硬体和软体时，应优先考虑互通性和标准合规性，以保护未来的投资并简化多中心研究合作。

我们采用综合性的多方法研究框架，结合文献整合、专家访谈、工具性证据和情境分析，为策略决策提供支援。

本研究采用整合多种证据来源的方法，对目前脑部影像技术现况进行稳健且有力的分析。主要调查方法包括系统性地回顾同行评审文献、监管文件和临床试验註册信息，以及与临床专家、成像科学家、采购负责人和技术供应商进行结构化访谈。这种综合分析利用仪器性能规格、示踪剂化学表征报告和运行案例研究，将技术能力与临床和研究应用案例相匹配。

简明扼要地整合了影响脑部影像临床和研究成功的技术进步、营运挑战和策略重点。

总之，影像硬体、示踪剂化学和分析技术的进步正在拓展临床医生和科学家可用的诊断和研究能力。这些进步为更精确的疾病表征、改进的手术计划和可靠的治疗监测创造了机会，但也要求在互通性、检验和人力资源准备方面进行有意识的投入。政策趋势和供应链的变化凸显了多样化筹资策略以及供应商和临床操作人员之间更紧密合作的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：脑部影像市场：依影像方式划分

  • 电脑断层扫描
    • 锥状射束
    • 传统的
  • 磁振造影
    • 血管造影术
    • 扩散
    • 功能性
    • 结构
  • 光学成像
    • FNIRS
    • 光学同调断层扫描
  • 正子断层扫描
    • 淀粉样蛋白
    • 多巴胺
    • FDG
  • 单光子发射电脑断层扫描
  • 超音波影像
    • 生物显微镜
    • 经颅都卜勒

第九章：依患者类型分類的脑部影像市场

  • 成人
  • 儿童
  • 婴儿

第十章：脑影像市场：依应用领域划分

  • 诊断
    • 癫痫
    • 神经退化性疾病
    • 创伤性脑损伤
    • 肿瘤检测
    • 血管疾病
  • 研究
    • 脑图谱
    • 神经科学
      • 基础研究
      • 临床研究
    • 药物研发
  • 治疗监测
    • 追踪疾病进展
    • 手术监测
    • 治疗效果评估

第十一章：脑部影像市场：依最终用户划分

  • 学术机构
    • 医学院
    • 大学
  • 门诊部
  • 诊断中心
  • 居家医疗
  • 医院
  • 研究机构
    • 政府研究机构
    • 私人研究机构

第十二章：脑造影市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：脑部影像市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 脑部影像市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国脑部影像市场

第十六章：中国脑部影像诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Advantis Medical Imaging
  • AiM Medical Robotics
  • Boston Scientific Corporation
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Elekta AB
  • EMVision Medical Devices Ltd.
  • Esaote SpA
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hitachi, Ltd.
  • Hologic, Inc.
  • Hyperfine Research, Inc.
  • Magnetic Insight, Inc.
  • Medtronic PLC
  • Octave Biosciences
  • Promaxo, Inc.
  • Royal Philips
  • Shimadzu Corporation
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • Toshiba Corporation
Product Code: MRR-5C6F41F5AF90

The Brain Imaging Modalities Market was valued at USD 15.37 billion in 2025 and is projected to grow to USD 16.90 billion in 2026, with a CAGR of 10.55%, reaching USD 31.04 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.37 billion
Estimated Year [2026] USD 16.90 billion
Forecast Year [2032] USD 31.04 billion
CAGR (%) 10.55%

An authoritative overview of contemporary brain imaging technologies and how convergence of modalities is reshaping clinical care and neuroscience research pathways

The study of brain imaging has matured into a multidisciplinary field that sits at the intersection of clinical neurology, surgical practice, neuroscience research, and biomedical engineering. Advances in instrumentation, data analytics, and tracer chemistry have expanded the portfolio of available modalities while elevating the clinical precision with which clinicians diagnose, monitor, and treat neurological disorders. As a result, imaging now informs everything from acute intervention planning to long-term therapeutic monitoring and basic mechanistic inquiry.

Technological refinements have driven improvements in spatial and temporal resolution, reduced acquisition times, and enabled safer, more patient-centric workflows, which in turn facilitate broader clinical adoption. Simultaneously, the proliferation of multimodal imaging approaches and integrated analytical pipelines has created new opportunities for cross-disciplinary collaboration, allowing clinicians and researchers to combine structural, functional, molecular, and hemodynamic information in a single diagnostic narrative. Consequently, imaging is increasingly central to personalized care pathways and to translational research paradigms that aim to close the gap between bench and bedside.

Looking ahead, implementation of scalable data standards, validation frameworks, and interoperable platforms will determine how rapidly new technologies translate into routine clinical use. With attention to regulatory compliance, reimbursement patterns, and clinician training, organizations can navigate the complexity of modality choice, clinical indication, and operational constraints to deliver measurable improvements in diagnostic accuracy and patient outcomes.

How advances in AI, portable instrumentation, hybrid imaging tracers, and interoperable analytics are reshaping clinical practice, research workflows, and diagnostic confidence

A number of transformative shifts are reconfiguring the brain imaging landscape, driven by technological innovation, data science, and evolving clinical needs. Artificial intelligence and advanced image analytics now augment human interpretation, enabling improved detection of subtle pathophysiology and the extraction of quantitative biomarkers that were previously inaccessible. At the same time, hardware innovation-such as higher field magnetic resonance systems, compact computed tomography units, and portable ultrasound-has expanded where and how imaging can be delivered, moving diagnostic capability closer to point-of-care settings.

Concurrently, molecular imaging tracers and hybrid systems have refined the capacity for in vivo biochemical mapping, which enhances diagnostic specificity for conditions such as neurodegenerative disease and focal epileptogenic zones. Integration between structural and functional modalities supports more accurate surgical planning and targeted therapeutic monitoring, while optical techniques have opened non-invasive windows for bedside neurovascular and hemodynamic assessment. As interoperability standards and cloud-native platforms mature, multi-site data aggregation increases the statistical power of research studies and accelerates clinical validation of novel biomarkers.

Consequently, stakeholders must adapt to an environment where technological choices are inseparable from data governance, clinical workflow redesign, and workforce competency. Providers that invest in scalable infrastructure, validate AI tools against robust ground truth, and cultivate multidisciplinary teams will capture the greatest clinical and operational value from these shifts.

Assessment of how the 2025 tariff environment reshaped supply reliability, procurement strategies, and research continuity for brain imaging stakeholders

Policy shifts enacted through tariff changes in 2025 created pronounced ripple effects across the global supply chain for brain imaging hardware, consumables, and ancillary services. Increased import duties on specialized components elevated lead times for large equipment and intermittent components, prompting manufacturers and health systems to reassess sourcing strategies. As a result, procurement cycles lengthened and capital planning required greater contingency buffering to maintain scheduled upgrades and installations.

Moreover, tariffs had heterogeneous effects across product categories. High-precision manufacturing elements used in computed tomography gantries, magnetic resonance gradient systems, and PET/SPECT detectors experienced supply pressure, whereas software and digital services, which predominantly travel electronically, were less directly affected. Consequently, some providers prioritized modular upgrades and software-driven improvements as near-term mitigations while deferring hardware refreshes. Research institutions were particularly sensitive to customs delays affecting radiochemistry kits and tracers used in molecular imaging, which complicated study timelines and regulatory submissions.

In response, industry actors accelerated diversification of manufacturing footprints, increased inventory of critical spares, and expanded regional partnerships to localize production where feasible. Simultaneously, strategic collaboration between device manufacturers, logistics providers, and clinical purchasers became essential to ensure continuity of service and to protect sensitive research schedules. Going forward, adaptations in procurement strategy, contract design, and supply chain visibility will remain central to managing policy-driven disruptions.

Deep segmentation insights synthesizing modality differences, application needs, and end-user constraints to guide procurement, R&D, and clinical deployment strategies

Segmentation-driven insights reveal nuanced patterns of adoption, clinical utility, and research allocation across modality, application, and end user dimensions. Based on modality, the landscape includes Computed Tomography, Magnetic Resonance Imaging, Optical Imaging, Positron Emission Tomography, Single Photon Emission Computer Tomography, and Ultrasound Imaging; within Computed Tomography, distinctions between Cone Beam and Conventional systems influence choices for interventional and surgical guidance, whereas Magnetic Resonance Imaging subdivides into Angiography, Diffusion, Functional, and Structural techniques that support vascular, white matter, functional connectivity, and anatomical assessments. Similarly, Optical Imaging encompasses functional near-infrared spectroscopy and optical coherence tomography, and Positron Emission Tomography differentiates among tracers such as amyloid, dopamine, and FDG, with Single Photon Emission Computer Tomography frequently focused on dopamine transporter imaging. Ultrasound Imaging remains bifurcated between biomicroscopy for high-resolution ocular and superficial tissue applications and transcranial Doppler for hemodynamic monitoring.

Based on application, the primary categories encompass Diagnostics, Research, and Therapeutic Monitoring; diagnostic subdomains include epilepsy, neurodegenerative disorders, traumatic brain injury, tumor detection, and vascular disease, each demanding specific modality strengths and tailored acquisition protocols. The research domain spans brain mapping, neuroscience, and pharmaceutical development, with neuroscience further divided into basic and clinical research, highlighting distinct validation, reproducibility, and ethics considerations. Therapeutic monitoring focuses on disease progression tracking, surgical monitoring, and treatment response assessment, where longitudinal consistency and biomarker robustness are critical to clinical decision making.

Based on end user, the ecosystem comprises academic institutions, ambulatory care facilities, diagnostic centers, home healthcare, hospitals, and research institutes; academic institutions further include medical schools and universities, while research institutes encompass government and private lab operators. Each end user has unique capital constraints, workflow needs, and regulatory exposures that shape procurement priorities. For example, academic and research settings prioritize flexible, high-throughput platforms and data accessibility for hypothesis generation, whereas hospitals emphasize integrated PACS, streamlined workflows, and reimbursement alignment for routine diagnostic throughput. Ambulatory and home care settings increasingly adopt compact and portable options that support decentralized patient pathways, and diagnostic centers balance cost efficiency with specialization to attract referral traffic.

Taken together, these segmentation layers demonstrate that modality choice cannot be decoupled from clinical indication, operational context, or end-user constraints. Stakeholders should therefore align procurement and development strategies to the specific demands of the modality-application-end user nexus to maximize clinical impact and operational efficiency.

Regional strategic considerations emphasizing how adoption, regulation, infrastructure, and supply chain localization differ across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape adoption curves, regulatory timelines, infrastructure investment, and supply chain resilience in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical consolidation, high levels of private investment, and established reimbursement pathways support rapid uptake of advanced imaging capabilities, particularly in tertiary hospital settings and research hubs. Conversely, this region also faces pressures from capital cycle optimization and an increased emphasis on value-based procurement, which drives interest in solutions that demonstrate clear outcomes and operational efficiencies.

In Europe Middle East & Africa, heterogeneous regulatory landscapes and variable infrastructure maturity lead to differentiated adoption patterns. Western European centers continue to lead in high-field MRI and molecular imaging applications, supported by integrated clinical research networks, while pockets in the Middle East and Africa show targeted investments in imaging infrastructure aimed at building regional centers of excellence. Cross-border collaboration and harmonized clinical trials are increasingly important, and stakeholders must navigate a patchwork of reimbursement regimes and data protection requirements to scale solutions continentally.

Asia-Pacific displays a dynamic mix of rapid technology adoption in urban tertiary centers, government-led modernization programs, and an expanding landscape of domestic manufacturers. High patient volumes accelerate innovation in throughput optimization and cost-effective imaging solutions, and regulatory bodies are increasingly aligning with international standards to support clinical trials and cross-jurisdictional device approval. Across all regions, local workforce training, supply chain localization, and culturally tailored clinical pathways remain critical to sustaining adoption and maximizing health system impact.

How corporate strategies, partnerships, and platform approaches are converging to accelerate validation and commercial adoption of advanced brain imaging solutions

Corporate behavior in the brain imaging ecosystem reflects a blend of capability consolidation, strategic partnerships, and targeted innovation aimed at closing clinical gaps. Established device manufacturers continue to prioritize integration of advanced image processing, AI-augmented interpretation, and service models that bundle equipment with lifecycle support. At the same time, specialized vendors and start-ups concentrate on niche capabilities such as tracer development, optical imaging modules, or advanced post-processing analytics, carving out value by addressing unmet clinical or research needs.

Partnerships between hardware suppliers, software developers, and clinical centers accelerate validation pathways and reduce time to adoption. These collaborations often include co-development agreements, joint clinical validation studies, and shared data access arrangements that facilitate regulatory submissions and broaden the evidence base. In parallel, companies are increasingly exploring as-a-service commercial models to lower barriers to adoption and to create recurring revenue streams that align vendor incentives with clinical outcomes.

Finally, corporate strategies that emphasize open platforms, interoperable standards, and clinician-centric workflows tend to achieve stronger adoption in complex health systems. Organizations that invest in transparent evidence generation, robust post-market surveillance, and scalable customer support position themselves to capture long-term value as imaging becomes more central to personalized neurology and translational research.

Practical, high-impact recommendations for executives and clinical leaders to strengthen resilience, validate innovations, and accelerate safe adoption of imaging advances

Industry leaders should adopt a pragmatic, action-oriented playbook that balances near-term operational resilience with long-term clinical innovation. First, diversify procurement and manufacturing relationships to reduce exposure to supply chain shocks and policy shifts, while simultaneously investing in inventory visibility tools that enable anticipatory sourcing. Second, prioritize interoperability and standards compliance when selecting imaging hardware and software to protect future investment and to streamline multi-site research collaborations.

Third, integrate AI and analytics through rigorous validation pipelines that include independent clinical testing, explainability assessments, and continuous performance monitoring in real-world settings. Fourth, align product development and clinical implementation with clear use case definitions and outcome metrics so that value can be demonstrated to payers and health system decision makers. Fifth, commit to workforce development by funding clinician training programs and cross-disciplinary teams that bridge radiology, neurology, and data science; this will accelerate uptake and ensure safe, effective utilization.

Lastly, pursue collaborative models that involve clinicians early in product design, leverage public-private partnerships for tracer and protocol development, and explore innovative commercial frameworks such as outcome-linked agreements. By taking these actions, organizations will be better positioned to convert technological advances into sustainable clinical and commercial value.

An integrated, multi-method research framework combining literature synthesis, expert interviews, device evidence, and scenario analysis to inform strategic decisions

The underlying research approach integrates multiple evidence streams to yield a robust and defensible analysis of the brain imaging landscape. Primary methodologies include systematic review of peer-reviewed literature, regulatory filings, and clinical trial registries, complemented by structured interviews with clinical experts, imaging scientists, procurement officers, and technology vendors. The synthesis draws on device performance specifications, tracer chemistry reports, and operational case studies to map technology capabilities to clinical and research use cases.

Data triangulation is a central pillar of the method, combining qualitative expert insight with quantitative indicators such as equipment deployment patterns, trial enrollment distributions, and citation-based scholarly activity. Scenario analysis is used to assess the implications of external drivers-such as policy shifts, reimbursement changes, and supply chain disruptions-while sensitivity assessments identify which variables have the greatest operational impact under alternative assumptions. Finally, ethical, regulatory, and data governance considerations are evaluated to ensure that recommendations are aligned with prevailing clinical standards and patient safety norms.

A concise synthesis of technological advances, operational imperatives, and strategic priorities that will determine clinical and research success in brain imaging

In summary, advances in imaging hardware, tracer chemistry, and analytics are collectively expanding the diagnostic and research capabilities available to clinicians and scientists. These advances create opportunities for more precise disease characterization, improved surgical planning, and robust therapeutic monitoring, but they also demand intentional investments in interoperability, validation, and workforce readiness. Policy developments and supply chain shifts emphasize the need for diversified procurement strategies and for closer collaboration between vendors and clinical operators.

For stakeholders across hospitals, research institutes, and commercial organizations, the imperative is to translate technological potential into reproducible clinical value through disciplined evidence generation and patient-centered implementation. By focusing on validated use cases, standardized data practices, and multisector partnerships, organizations can deploy imaging innovations that improve outcomes, reduce diagnostic uncertainty, and support translational research agendas. The future of brain imaging will be defined less by individual technologies and more by the systems that integrate them safely, efficiently, and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Imaging Modalities Market, by Modality

  • 8.1. Computed Tomography
    • 8.1.1. Cone Beam
    • 8.1.2. Conventional
  • 8.2. Magnetic Resonance Imaging
    • 8.2.1. Angiography
    • 8.2.2. Diffusion
    • 8.2.3. Functional
    • 8.2.4. Structural
  • 8.3. Optical Imaging
    • 8.3.1. Fnirs
    • 8.3.2. Optical Coherence Tomography
  • 8.4. Positron Emission Tomography
    • 8.4.1. Amyloid
    • 8.4.2. Dopamine
    • 8.4.3. Fdg
  • 8.5. Single Photon Emission Computer Tomography
  • 8.6. Ultrasound Imaging
    • 8.6.1. Biomicroscopy
    • 8.6.2. Transcranial Doppler

9. Brain Imaging Modalities Market, by Patient Type

  • 9.1. Adults
  • 9.2. Pediatrics
  • 9.3. Infants

10. Brain Imaging Modalities Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Epilepsy
    • 10.1.2. Neurodegenerative Disorders
    • 10.1.3. Traumatic Brain Injury
    • 10.1.4. Tumor Detection
    • 10.1.5. Vascular Disease
  • 10.2. Research
    • 10.2.1. Brain Mapping
    • 10.2.2. Neuroscience
      • 10.2.2.1. Basic Research
      • 10.2.2.2. Clinical Research
    • 10.2.3. Pharmaceutical Development
  • 10.3. Therapeutic Monitoring
    • 10.3.1. Disease Progression Tracking
    • 10.3.2. Surgical Monitoring
    • 10.3.3. Treatment Response Assessment

11. Brain Imaging Modalities Market, by End User

  • 11.1. Academic Institutions
    • 11.1.1. Medical Schools
    • 11.1.2. Universities
  • 11.2. Ambulatory Care Facilities
  • 11.3. Diagnostic Centers
  • 11.4. Home Healthcare
  • 11.5. Hospitals
  • 11.6. Research Institutes
    • 11.6.1. Government Labs
    • 11.6.2. Private Labs

12. Brain Imaging Modalities Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Brain Imaging Modalities Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Brain Imaging Modalities Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Brain Imaging Modalities Market

16. China Brain Imaging Modalities Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Advantis Medical Imaging
  • 17.7. AiM Medical Robotics
  • 17.8. Boston Scientific Corporation
  • 17.9. Bruker Corporation
  • 17.10. Canon Medical Systems Corporation
  • 17.11. Elekta AB
  • 17.12. EMVision Medical Devices Ltd.
  • 17.13. Esaote SpA
  • 17.14. Fujifilm Holdings Corporation
  • 17.15. GE HealthCare Technologies, Inc.
  • 17.16. Hitachi, Ltd.
  • 17.17. Hologic, Inc.
  • 17.18. Hyperfine Research, Inc.
  • 17.19. Magnetic Insight, Inc.
  • 17.20. Medtronic PLC
  • 17.21. Octave Biosciences
  • 17.22. Promaxo, Inc.
  • 17.23. Royal Philips
  • 17.24. Shimadzu Corporation
  • 17.25. Siemens AG
  • 17.26. Thermo Fisher Scientific Inc.
  • 17.27. Toshiba Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN IMAGING MODALITIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN IMAGING MODALITIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONE BEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ANGIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIFFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY STRUCTURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FNIRS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMYLOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DOPAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BIOMICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY INFANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY INFANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TUMOR DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY VASCULAR DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BRAIN MAPPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PHARMACEUTICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DISEASE PROGRESSION TRACKING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY SURGICAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY TREATMENT RESPONSE ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY MEDICAL SCHOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY AMBULATORY CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GOVERNMENT LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GOVERNMENT LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GOVERNMENT LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PRIVATE LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY PRIVATE LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 290. GLOBAL BRAIN IMAGING MODALITIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY OPTICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY ULTRASOUND IMAGING, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY NEUROSCIENCE, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY THERAPEUTIC MONITORING, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN BRAIN IMAGING MODALITIES MARKET SIZE, BY END U